Literature DB >> 25761729

Projection of osteoporosis-related fractures and costs in China: 2010-2050.

L Si1, T M Winzenberg, Q Jiang, M Chen, A J Palmer.   

Abstract

UNLABELLED: A state-transition microsimulation model was used to project the substantial economic burden to the Chinese healthcare system of osteoporosis-related fractures. Annual number and costs of osteoporosis-related fractures were estimated to double by 2035 and will increase to 5.99 (95 % CI 5.44, 6.55) million fractures costing $25.43 (95 % CI 23.92, 26.95) billion by 2050. Consequently, cost-effective intervention policies must urgently be identified in an attempt to minimize the impact of fractures.
INTRODUCTION: The aim of the study was to project the osteoporosis-related fractures and costs for the Chinese population aged ≥50 years from 2010 to 2050.
METHODS: A state-transition microsimulation model was used to simulate the annual incident fractures and costs. The simulation was performed with a 1-year cycle length and from the Chinese healthcare system perspective. Incident fractures and annual costs were estimated from 100 unique patient populations for year 2010, by multiplying the age- and sex-specific annual fracture risks and costs of fracture by the corresponding population totals in each of the 100 categories. Projections for 2011-2050 were performed by multiplying the 2010 risks and costs of fracture by the respective annual population estimates. Costs were presented in 2013 US dollars.
RESULTS: Approximately 2.33 (95 % CI 2.08, 2.58) million osteoporotic fractures were estimated to occur in 2010, costing $9.45 (95 % CI 8.78, 10.11) billion. Females sustained approximately three times more fractures than males, accounting for 76 % of the total costs from 1.85 (95 % CI 1.68, 2.01) million fractures. The annual number and costs of osteoporosis-related fractures were estimated to double by 2035 and will increase to 5.99 (95 % CI 5.44, 6.55) million fractures costing $25.43 (95 % CI 23.92, 26.95) billion by 2050.
CONCLUSIONS: Our study demonstrated that osteoporosis-related fractures cause a substantial economic burden which will markedly increase over the coming decades. Consequently, healthcare resource planning must consider these increasing costs, and cost-effective screening and intervention policies must urgently be identified in an attempt to minimize the impact of fractures on the health of the burgeoning population as well as the healthcare budget.

Entities:  

Mesh:

Year:  2015        PMID: 25761729     DOI: 10.1007/s00198-015-3093-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  35 in total

Review 1.  Treatment of established osteoporosis: a systematic review and cost-utility analysis.

Authors:  J A Kanis; J E Brazier; M Stevenson; N W Calvert; M Lloyd Jones
Journal:  Health Technol Assess       Date:  2002       Impact factor: 4.014

2.  Hip fracture and increased short-term but not long-term mortality in healthy older women.

Authors:  Erin S LeBlanc; Teresa A Hillier; Kathryn L Pedula; Joanne H Rizzo; Peggy M Cawthon; Howard A Fink; Jane A Cauley; Douglas C Bauer; Dennis M Black; Steven R Cummings; Warren S Browner
Journal:  Arch Intern Med       Date:  2011-09-26

3.  A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050.

Authors:  Amanda A Honeycutt; James P Boyle; Kristine R Broglio; Theodore J Thompson; Thomas J Hoerger; Linda S Geiss; K M Venkat Narayan
Journal:  Health Care Manag Sci       Date:  2003-08

Review 4.  A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions.

Authors:  L Si; T M Winzenberg; B de Graaff; A J Palmer
Journal:  Osteoporos Int       Date:  2014-02-22       Impact factor: 4.507

5.  Reference values of bone mineral density and prevalence of osteoporosis in Chinese adults.

Authors:  Z-Q Zhang; S C Ho; Z-Q Chen; C-X Zhang; Y-M Chen
Journal:  Osteoporos Int       Date:  2013-06-26       Impact factor: 4.507

6.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

7.  Epidemiology of distal forearm fractures in Oslo, Norway.

Authors:  C M Lofthus; F Frihagen; H E Meyer; L Nordsletten; K Melhuus; J A Falch
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

8.  Forecasting the future economic burden of current adolescent overweight: an estimate of the coronary heart disease policy model.

Authors:  James Lightwood; Kirsten Bibbins-Domingo; Pamela Coxson; Y Claire Wang; Lawrence Williams; Lee Goldman
Journal:  Am J Public Health       Date:  2009-10-15       Impact factor: 9.308

Review 9.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

Review 10.  The Asia-Pacific Regional Audit-Epidemiology, Costs, and Burden of Osteoporosis in India 2013: A report of International Osteoporosis Foundation.

Authors:  Ambrish Mithal; Beena Bansal; Carey S Kyer; Peter Ebeling
Journal:  Indian J Endocrinol Metab       Date:  2014-07
View more
  104 in total

1.  Cross-cultural adaptation and validation of the osteoporosis assessment questionnaire short version (OPAQ-SV) for Chinese osteoporotic fracture females.

Authors:  Yin-Ping Zhang; Huan-Huan Wei; Wen Wang; Ru-Yi Xia; Xiao-Ling Zhou; Caroline Porr; Mikko Lammi
Journal:  Clin Rheumatol       Date:  2015-07-15       Impact factor: 2.980

2.  Using epigenomic data to inform genome-wide association studies of bone mineral density.

Authors:  John A Morris
Journal:  Ann Transl Med       Date:  2016-12

Review 3.  Economic burden of osteoporosis-related hip fracture in Asia: a systematic review.

Authors:  N-A Mohd-Tahir; S-C Li
Journal:  Osteoporos Int       Date:  2017-03-17       Impact factor: 4.507

4.  Comparison of strategies for setting intervention thresholds for Chinese postmenopausal women using the FRAX model.

Authors:  Shu-Ying Liu; Meng Huang; Rong Chen; Na Ding; Hong Liu; Zhong-Jian Xie; Zhi-Feng Sheng; Bi-Hua Luo; Yang-Na Ou
Journal:  Endocrine       Date:  2019-05-20       Impact factor: 3.633

5.  [Evaluation of screening accuracy on osteoporosis self-assessment tool for Asians and its cut-off value in healthy physical examination population].

Authors:  P Wang; H Wu; Y Che; D W Fan; J Liu; L Y Tao
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-18

Review 6.  Quality Improvement Initiatives in Fragility Fracture Care and Prevention.

Authors:  Paul J Mitchell; Cyrus Cooper; Masaki Fujita; Philippe Halbout; Kristina Åkesson; Matthew Costa; Karsten E Dreinhöfer; David R Marsh; Joon-Kiong Lee; Ding-Cheng Derrick Chan; M Kassim Javaid
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

7.  Current status and distribution of hip fractures among older adults in China.

Authors:  X F Gong; X P Li; L X Zhang; J R Center; D Bliuc; Y Shi; H B Wang; L He; X B Wu
Journal:  Osteoporos Int       Date:  2021-03-02       Impact factor: 4.507

8.  Efficacy of autologous bone marrow derived Mesenchymal stem cells (MSCs), osteoblasts and osteoblasts derived exosome in the reversal of ovariectomy (OVX) induced osteoporosis in rabbit model.

Authors:  Mir Sadat-Ali; Dakheel A Al-Dakheel; Haifa A Al-Turki; Sadananda Acharya
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

9.  Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study.

Authors:  L Si; T M Winzenberg; M Chen; Q Jiang; A Neil; A J Palmer
Journal:  Osteoporos Int       Date:  2016-01-27       Impact factor: 4.507

Review 10.  Systematic scoping review of patients' perceived needs of health services for osteoporosis.

Authors:  L Chou; P Shamdasani; A M Briggs; F M Cicuttini; K Sullivan; K L M D Seneviwickrama; A E Wluka
Journal:  Osteoporos Int       Date:  2017-07-31       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.